Evaluation of M118 IN pErcutaNeous Coronary intErvention - EMINENCE

Description:

This was a phase II trial comparing three doses of intravenous M118 (a novel synthetic anticoagulant with both antithrombin and anti Xa activity) with unfractionated heparin (UFH) in patients undergoing elective percutaneous coronary intervention (PCI).